When leptomeningeal metastasis develops in the context of ALK-positive non-small-cell lung cancer, the ALK-positive status of the primary tumour is a central consideration in treatment selection.
A systemic agent has been studied in a phase II trial enrolling patients with confirmed or probable leptomeningeal involvement from ALK-positive NSCLC.
The complete regimen — including agent, eligibility criteria, and the full clinical algorithm — is available in the structured protocol.
DOI: 10.1016/j.esmoop.2023.101624
A phase II trial was also carried out exploring ceritinib in 18 patients with confirmed or probable LM from ALK-positive NSCLC.
View source ↗